Sunshine Biopharma (SBFM) is definitely bringing some sunshine for its shareholders today. At the highest price of $6.80 today, which also is all time record highs, the stock was up over 180% for the day!
I know a few biotech investors who probably played this. Even for us junior mining guys, the moves we see in small cap biotech are insane!
It all comes down to that catalyst, and nothing drives biotech prices higher than trial results. And boy, did Sunshine Biopharma unveil some big news to combat that disease we all hate. Cancer.
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, Sunshine is engaged in the development and commercialization of science-based nutritional supplements. The company is a Colorado corporation headquartered in Montreal, Canada.
The two major drugs in development for the company are a COVID-19 treatment, with Sunshine Biopharma filing a patent application covering protease inhibitors on May 22nd 2020, and an anti cancer drug Adva-27a.
Since inception, Sunshine Biopharma has been focused on the development of Adva-27a, a small molecule that has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Adva-27a is the only compound known that is capable of destroying Multidrug Resistant Cancer Cells. The Company is planning to conduct Adva-27a Phase I Clinical Trials for Pancreatic Cancer indication at McGill University’s Jewish General Hospital in Montreal (Canada).
On April 5th 2022, the company announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture. Here are details from the press release:
The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. These new mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology. The Company anticipates filing a patent application in connection with these results soon.
“We are delighted by these findings in connection with our ongoing mRNA-as-therapeutic-agents research,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “The potential use of mRNA to treat cancer opens the door to many possibilities for patients including convenience, reduced toxicity and enhanced efficacy,” he added.
